e-therapeutics plc Share Price London S.E.

Equities

ETX

GB00B2823H99

Biotechnology & Medical Research

Delayed London S.E. 16:35:15 08/05/2024 BST 5-day change 1st Jan Change
9 GBX -6.74% Intraday chart for e-therapeutics plc 0.00% +9.22%
Current month-8.86%
1 month-1.91%
Sales 2022 0.48 37.45 Sales 2023 0.48 37.29 Capitalization 120M 9.38B
Net income 2022 -8M -628M Net income 2023 -8M -628M EV / Sales 2022 306,593,257 x
Net cash position 2022 25.96M 2.04B Net cash position 2023 31.39M 2.46B EV / Sales 2023 185,557,271 x
P/E ratio 2022
-20.3 x
P/E ratio 2023
-13.3 x
Employees 34
Yield 2022 *
-
Yield 2023
-
Free-Float 29.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.74%
Current month-8.86%
1 month-1.91%
3 months-34.43%
6 months-9.86%
Current year+9.22%
More quotes
1 month
9.00
Extreme 9
11.40
Current year
8.02
Extreme 8.02
18.72
1 year
8.00
Extreme 8
24.00
3 years
8.00
Extreme 8
49.50
5 years
1.40
Extreme 1.4
49.50
10 years
1.40
Extreme 1.4
49.50
More quotes
e-therapeutics plc is a United Kingdom-based company engaged in integrating computational power and biological data to discover life-transforming RNA interference (RNAi) medicines. The Company's technology uses computation to capture and model human biology, identify targets, and develop RNAi medicines against those targets that can be progressed to the clinic. Its HepNet platform enables the generation and analysis of biological network models, providing a mechanistic approach to drug discovery. Its RNAi platform, GalOmic, enables targeted delivery to hepatocytes in the liver and the specific silencing of disease-associated genes, identified by HepNet. The Company is progressing a pipeline of RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, hemophilia, and other undisclosed indications. Its pipeline includes ETX-312, ETX-407, ETX-148, ETX-291 and others.
More about the company